trending Market Intelligence /marketintelligence/en/news-insights/trending/7HaTaxJt3qkQeMZhrGHM7A2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Regeneron halts development of respiratory treatment for infants

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Regeneron halts development of respiratory treatment for infants

Regeneron Pharmaceuticals Inc.'s suptavumab failed to meet its primary endpoint of preventing respiratory syncytial virus infections in preterm infants in a phase 3 study.

The infection known as RSV is a common virus that leads to cold-like symptoms in adults but can be more serious in young infants. Suptavumab is an antibody to RSV.

Regeneron plans to discontinue further clinical development for the treatment, the company said in a news release.